Overview of HIV Prevention

  • Author: Sharon L. Hillier, PhD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/24/18 (What's New)

Summary

  • The use of topical tenofovir gel evaluated as PrEP in HIV-uninfected women
    • CAPRISA 004 study found that tenofovir 1% gel reduced HIV acquisition by 39% overall and by 54% among women with adherence > 80%[Abdool Karim 2010]
    • VOICE and FACTS-001 trials found that topical tenofovir had no protective effect against HIV infection[Marrazzo 2015; Rees 2015]

Action required

Keywords: Biomedical Prevention

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.